GoAI
Get started
Savara Inc. logo

Savara Inc.

SVRA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.59

+$0.10 · +1.82%

Aug 21, 4:00 PM ET

Pre-market

$5.60

+$0.01 · +0.18%

Aug 24, 4:00 AM ET

SVRA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

32

Expensive

Momentum

65

Gaining

Sentiment

50

Mixed

Risk resilience

68

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Matthew Pauls
Listed since
Apr 28, 2017
Employees
70

Market position

Day range

Current $5.59

52-week range

Current $5.59

Open
$5.54
Previous close
$5.49
Volume
3.04M
1.85× average
Average volume
1.64M
Average daily volume
Market cap
1.15B USD
Beta
0.26
Market reference 1
50-day average
$5.6666
-1.35% below average
200-day average
$5.518
+1.30% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.34B USD
P/E (TTM)
-9.64×
P/B (TTM)
9.87×
P/S (TTM)
0×
EV / EBITDA
-11.28×
Earnings yield
-8.86%
Free cash flow yield
-7.54%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-58.50%
Return on assets
-46.89%
Return on invested capital
-53.01%

Financial health

Debt / equity
0.21×
Current ratio
11.85×
Altman Z-score
7.79
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−123.55M USD-19.72%

Net income

−118.84M USD-23.94%
Income trends across reported periods−29.61M USD−63.77M USD−97.93M USD−132.09M USDOperating income, FY2021: −41.48M USDOperating income, FY2022: −38.84M USDOperating income, FY2023: −60.01M USDOperating income, FY2024: −103.2M USDOperating income, FY2025: −123.55M USDNet income, FY2021: −43.01M USDNet income, FY2022: −38.15M USDNet income, FY2023: −54.7M USDNet income, FY2024: −95.88M USDNet income, FY2025: −118.84M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −41.48M USD. Operating income FY2022 −38.84M USD. Operating income FY2023 −60.01M USD. Operating income FY2024 −103.2M USD. Operating income FY2025 −123.55M USD. Net income FY2021 −43.01M USD. Net income FY2022 −38.15M USD. Net income FY2023 −54.7M USD. Net income FY2024 −95.88M USD. Net income FY2025 −118.84M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold245K USD78.03M USD44.26M USD27.88M USD28.99M USD
Gross profit−245K USD−78.03M USD−44.26M USD−27.88M USD−28.99M USD
Research and development81.4M USD78.03M USD44.26M USD27.88M USD28.99M USD
Selling, general, and administrative42.06M USD25.04M USD15.67M USD10.93M USD12.35M USD
Operating expenses123.3M USD25.17M USD15.75M USD10.96M USD12.49M USD
Interest income4.16M USD6.47M USD4.44M USD88 USD2.28K USD
Interest expense———88K USD2.28M USD
Depreciation and amortization245K USD130K USD77K USD31K USD136K USD
Operating income−123.55M USD−103.2M USD−60.01M USD−38.84M USD−41.48M USD
Net income−118.84M USD−95.88M USD−54.7M USD−38.15M USD−43.01M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
9%
1 beat, 8 misses, 2 met estimates
Average EPS surprise
-6.56%
11 comparable reports
Latest EPS result
-0.16
Estimate -0.14 · Miss by 13.27%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.13-0.16-0.2Q1 '25MissQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.13, estimate -0.11, surprise -18.18%, Miss. Q2 2025, reported May 13, 2025: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q3 2025, reported Aug 13, 2025: actual -0.14, estimate -0.12, surprise -16.67%, Miss. Q4 2025, reported Nov 12, 2025: actual -0.14, estimate -0.13, surprise -7.69%, Miss. Q1 2026, reported Mar 13, 2026: actual -0.13, estimate -0.12, surprise -8.33%, Miss. Q2 2026, reported May 12, 2026: actual -0.15, estimate -0.14, surprise -7.14%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.16, estimate -0.141, surprise -13.27%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.16, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.14M1.5M866.88K231.2KQ1 '25No estimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 272K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual —, estimate 500K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 11, 2026: actual —, estimate 2M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 11, 2026: actual —, estimate 500K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.00

78.89% upside
Past 12 months12-month forecastHigh $10.00Average $10.00Low $10.00

Rating distribution

11 ratings
Strong buy00%
Buy982%
Hold218%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions
CitizensmaintainMarket Outperform

Corporate actions

Corporate action history

Stock split

Effective Apr 28, 2017

1:70

Stock split

Effective Apr 26, 2010

1:25

Stock split

Effective Jun 11, 2002

251:500

SVRA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SVRA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
33.66M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
21.64M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
18.42M
Weight
0.16%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
8.58M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
7.89M
Weight
0.05%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
4.69M
Weight
0.03%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
4.35M
Weight
0.04%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
F/M Emerald Life Sciences Innovation ETF logoF/M Emerald Life Sciences Innovation ETFLFSC
Market value
3.74M
Weight
2.85%
AUM
74.65M USD
Expense ratio
0.54%
Price / 1D
$47.7953+0.83%

Continue in GoAI

Research SVRA

research.disclaimer